Tarsus holder plans $127K stock sale

Tarsus Pharmaceuticals, Inc. (TARS) is the issuer of common stock for which Elizabeth Yeu-Lin, through an account at Fidelity Brokerage Services LLC, has filed a notice of a proposed sale under Rule 144.

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. (TARS) is the issuer of common stock for which Elizabeth Yeu-Lin, through an account at Fidelity Brokerage Services LLC, has filed a notice of a proposed sale under Rule 144. The notice covers 1,590 shares of common stock with an aggregate market value of $127,200.00, based on 43,882,996 shares outstanding as of September 2, 2026 on NASDAQ. A related person, identified in the remarks as spouse Stephen Lin, previously sold 4,601 shares of Tarsus common stock for $339,829.86 on September 1, 2026.

Key Figures

Shares proposed for sale: 1,590 shares Aggregate market value of proposed sale: $127,200.00 Shares outstanding: 43,882,996 shares +4 more

7 metrics

Shares proposed for sale 1,590 shares Common stock referenced in the Rule 144 notice

Aggregate market value of proposed sale $127,200.00 Market value associated with 1,590 shares of Tarsus common stock

Shares outstanding 43,882,996 shares Common stock outstanding as of September 2, 2026

Recent shares sold 4,601 shares Common stock sold on September 1, 2026 by spouse Stephen Lin

Proceeds from recent sale $339,829.86 Total consideration for 4,601 shares sold on September 1, 2026

Date of notice September 2, 2026 Date on which the Rule 144 notice is dated

Acquisition date of proposed-sale shares September 14, 2022 Date 1,590 shares were acquired by open market purchase for cash

Key Terms

Rule 144, Open Market Purchase, attorney-in-fact, aggregate market value

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Open Market Purchase financial

"Common | 09/14/2022 | Open Market Purchase | Issuer"

An open market purchase is when a company buys its own shares on public stock exchanges the same way any investor would, rather than through a private deal. Investors care because these purchases reduce the number of shares available, can boost earnings per share and share price, signal that management thinks the stock is undervalued, and use company cash that might otherwise go to reinvestment or dividends — like a business quietly buying back its own tickets at the box office.

attorney-in-fact regulatory

"as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Elizabeth Yeu-Lin"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

aggregate market value financial

"Common | Fidelity Brokerage Services LLC ... | 1590 | 127200.00 | 43882996"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

What does the Form 144 notice involving TARS disclose?

It discloses a proposed Rule 144 sale related to Tarsus Pharmaceuticals, Inc. common stock. The notice covers 1,590 shares with an aggregate market value of $127,200.00, and also reports a prior sale of 4,601 shares for $339,829.86 in the past three months.

How many Tarsus Pharmaceuticals (TARS) shares are proposed to be sold?

The notice covers a proposed sale of 1,590 shares of Tarsus Pharmaceuticals, Inc. common stock. These shares are held in an account at Fidelity Brokerage Services LLC and are referenced with an aggregate market value of $127,200.00 at the time of the notice.

What recent TARS stock sales are reported for the past three months?

A related person, identified in the remarks as spouse Stephen Lin, sold 4,601 shares of Tarsus Pharmaceuticals common stock on September 1, 2026 for total proceeds of $339,829.86. This sale is reported as part of the required three-month sales history.

How many Tarsus Pharmaceuticals (TARS) shares were outstanding as referenced in the notice?

The notice states that there were 43,882,996 shares of Tarsus Pharmaceuticals, Inc. common stock outstanding as of September 2, 2026. This figure is used in the Rule 144 disclosure as context for the proposed sale.

Who is the person for whose account the TARS securities are to be sold?

The securities are for the account of Elizabeth Yeu-Lin. The remarks explain that the reported sale activity took place in the account of her spouse, Stephen Lin, with Fidelity Brokerage Services LLC acting and signing as attorney-in-fact on her behalf.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:32 PM Accepted by SEC EDGAR 09/02/2026 - 04:31 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001842190
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Tarsus Pharmaceuticals, Inc.
SEC File Number	001-39614
Address of Issuer	15440 LAGUNA CANYON ROAD IRVINE CALIFORNIA 92618
Phone	(949) 409-9820
Name of Person for Whose Account the Securities are To Be Sold	Lin Elizabeth Yeu
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Member of immediate family of any of the foregoing

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	1590	127200.00	43882996	09/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/14/2022	Open Market Purchase	Issuer			1590	09/14/2022	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Elizabeth Yeu-Lin 17700 Laguna Canyon Road Floor 4 Irvine CA 92618	Common	09/01/2026	4601	339829.86

144: Remarks and Signature

Remarks	This sale took place in the account of Stephen Lin who is the spouse of Elizabeth Yeu-Lin.
Date of Notice	09/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/29/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Adam Gehring, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Elizabeth Yeu-Lin
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)